Novo, Catalio Capital Management and SymBiosis led a $100m Series B extension round in Metagenomi, a genetic medicines company with a versatile portfolio of wholly owned, next-generation gene editing systems. "At Novo Holdings, our purpose is to improve people’s health and the sustainability of society and the planet. Metagenomi continues to display an impressive track record of rapidly developing novel gene editing systems and advancing them through preclinical validation," Ray Camahort, Novo Partner.